Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Working Capital Changes (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Working Capital Changes for 7 consecutive years, with -$21.3 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 251.24% to -$21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 861.61% year-over-year, with the annual reading at $2.4 million for FY2025, 861.61% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$21.3 million at Kymera Therapeutics, down from -$2.8 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $38.0 million in Q3 2024, with the low at -$38.1 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$1.7 million, with a median of -$2.2 million recorded in 2021.
  • Peak annual rise in Other Working Capital Changes hit 9784.64% in 2024, while the deepest fall reached 2206.42% in 2024.
  • Over 5 years, Other Working Capital Changes stood at -$2.1 million in 2021, then tumbled by 1729.62% to -$38.1 million in 2022, then surged by 93.66% to -$2.4 million in 2023, then tumbled by 150.89% to -$6.1 million in 2024, then plummeted by 251.24% to -$21.3 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$21.3 million, -$2.8 million, and $29.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.